Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Janel A M PetersonDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX 77030.ORCID 0000-0001-8907-8581
Jesus A FriasDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX 77030.
Andrew N MillerDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX 77030.
Krishnakant G SoniDivision of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX 77030.
Yi ZhangBiomedical Engineering Department, Oregon Health and Science University, Portland, OR 97239.ORCID 0000-0001-5680-4647
Zheng XiaBiomedical Engineering Department, Oregon Health and Science University, Portland, OR 97239.ORCID 0000-0003-3364-8324
John W DayDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305.
Geoffrey A PreidisDivision of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX 77030.ORCID 0000-0002-2206-6452
Thomas A CooperDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX 77030.ORCID 0000-0002-9238-0578
Funding
Mechanisms of Skeletal Muscle Pathogenesis in Myotonic Dystrophy Type 1R01AR082852 · NIAMS · BAYLOR COLLEGE OF MEDICINE · PI Thomas A Cooper · 2023 to 2026
$2.5M
The metabolic basis for impaired bile acid synthesis in malnutritionR01DK133301 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Geoffrey A Preidis · 2022 to 2026
$2.2M
Pathogenic mechanisms and therapeutics for the cardiac manifestations of myotonic dystrophy type 1R01HL147020 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI COOPER, THOMAS A · 2019 to 2022
$1.7M
Characterizing phenotype-associated subpopulations from single-cell sequencing dataR01GM147365 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Zheng Xia · 2023 to 2026
$1.2M
MBNL loss of function in visceral smooth muscle as a model of myotonic dystrophy type 1F31DK132935 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI PETERSON, JANEL ANN MERKEL · 2023 to 2025
$149k
HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL147020HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01AR082852HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1F31DK132935HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK133301HHS | NIH | National Institute of General Medical Sciences (NIGMS) R01GM147365NHLBI NIH HHS R01 HL147020NIAMS NIH HHS R01 AR082852NIDDK NIH HHS F31 DK132935
6 · The paper itself
Abstract
Myotonic dystrophy type 1 (DM1) is the most common adult-onset muscular dystrophy and severely affects multiple organ systems, including the brain, heart, skeletal muscle, and gastrointestinal (GI) tract. Despite 80% of individuals with DM1 experiencing GI dysfunction that affects their daily life, the mechanisms of GI dysmotility in DM1 remain an understudied aspect of the disease. DM1 is caused by a CTG repeat expansion in the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
MBNL loss of function in smooth muscle as a model for myotonic dystrophy associated gastrointestinal dysmotility. · full record | Socratic